These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35638227)

  • 41. Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine: A pilot study.
    Adachi E; Ikeuchi K; Koga M; Yotsuyanagi H
    J Infect Chemother; 2023 Jan; 29(1):109-111. PubMed ID: 36116718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
    Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
    HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.
    Schmidt HA; Rodolph M; Schaefer R; Baggaley R; Doherty M
    J Int AIDS Soc; 2022 Jul; 25(7):e25963. PubMed ID: 35903882
    [No Abstract]   [Full Text] [Related]  

  • 44. Cabotegravir Plus Rilpivirine: First Approval.
    Markham A
    Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.
    Pinto RM; Hall E; Tomlin R
    J Assoc Nurses AIDS Care; 2023 Mar-Apr 01; 34(2):216-220. PubMed ID: 36662654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 47. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
    Navarro J; González-Cordón A; Casado JL; Bernardino JI; Domingo P; Portilla J; Llibre JM; Colomer J; Rial-Crestelo D; Vizcarra P; Curran A; Martínez E; Ribera E
    J Antimicrob Chemother; 2020 Jul; 75(7):1955-1960. PubMed ID: 32134108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
    Ahluwalia AK; Inzaule S; Baggaley RC; Vitoria M; Schaefer R; Schmidt HA; Rodolph M; Giron A; Jordan MR
    AIDS; 2022 Nov; 36(13):1897-1898. PubMed ID: 36172874
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
    Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
    Murray M; Antela A; Mills A; Huang J; Jäger H; Bernal E; Lombaard J; Katner H; Walmsley S; Khuong-Josses MA; Hudson K; Dorey D; Griffith S; Spreen W; Vanveggel S; Shaefer M; Margolis D; Chounta V
    AIDS Behav; 2020 Dec; 24(12):3533-3544. PubMed ID: 32447500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First Extended-Release Injectable Drug Therapy for HIV.
    Aschenbrenner DS
    Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
    Scarsi KK; Swindells S
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211009011. PubMed ID: 33902356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cabotegravir and Rilpivirine.
    Am J Health Syst Pharm; 2021 May; 78(11):925-931. PubMed ID: 33822851
    [No Abstract]   [Full Text] [Related]  

  • 55. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
    Cutrell AG; Schapiro JM; Perno CF; Kuritzkes DR; Quercia R; Patel P; Polli JW; Dorey D; Wang Y; Wu S; Van Eygen V; Crauwels H; Ford SL; Baker M; Talarico CL; Clair MS; Jeffrey J; White CT; Vanveggel S; Vandermeulen K; Margolis DA; Aboud M; Spreen WR; van Lunzen J
    AIDS; 2021 Jul; 35(9):1333-1342. PubMed ID: 33730748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
    PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
    Theys K; Van Laethem K; Gomes P; Baele G; Pineda-Peña AC; Vandamme AM; Camacho RJ; Abecasis AB
    AIDS Res Hum Retroviruses; 2016 May; 32(5):427-33. PubMed ID: 26651266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
    Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
    J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 60. The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa.
    Dawood H
    Lancet Glob Health; 2021 May; 9(5):e563-e564. PubMed ID: 33770512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.